title: Does finding early recurrence improve outcomes, and at what cost?
abstract: The putative goal of surveillance is the early detection of recurrence while both the cancer and patient are still treatable. To be cost and clinically effective, surveillance requires a tailored approach based on stage, tumor biology, conditional survival, and available treatment options. Although surveillance is the major component of care for cancer patients after potentially curative treatment, current guidelines for surveillance lack the high-level data seen on the treatment side of the patient care continuum. J. Surg. Oncol. 2016;114:329-335. © 2016 Wiley Periodicals, Inc.
authors.affiliation: Department of Surgery, University of Kentucky Medical Center, Lexington, Kentucky.
authors.forename: Anh-Thu
authors.initials: AT
authors.lastname: Le
authors.affiliation: Department of Surgery, University of Kentucky Medical Center, Lexington, Kentucky.
authors.forename: Ching-Wei D
authors.initials: CW
authors.lastname: Tzeng
mesh_terms: D003362:Cost-Benefit Analysis; D004067:Digestive System Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D055088:Early Detection of Cancer / Q000191:economics*; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy; D009367:Neoplasm Staging; D016896:Treatment Outcome
keywords: cost-effectiveness; recurrence; surveillance; treatment